The recovery from taxane mediated apoptosis in PC-3 castration-resistant metastatic prostate cancer cells

被引:1
|
作者
Eskiler, Gamze Guney [1 ]
Ozkan, Asuman Deveci [1 ]
Elmas, Merve Acikel [2 ]
Ozturk, Melek [3 ]
Arbak, Serap [2 ]
机构
[1] Sakarya Univ, Fac Med, Dept Med Biol, Korucuk Campus, TR-54290 Sakarya, Turkiye
[2] Acibadem Mehmet Ali Aydinlar Univ, Sch Med, Dept Histol & Embryol, Istanbul, Turkiye
[3] Istanbul Cerrahpasa Univ, Fac Med, Dept Med Biol, Istanbul, Turkiye
关键词
Castration resistant metastatic prostate cancer; cells; Drug resistance; Apoptosis; Taxanes; Cabazitaxel; DNA-DAMAGE; CABAZITAXEL;
D O I
10.1016/j.tiv.2024.105894
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Here, we revealed the reversibility of cabazitaxel (CBZ)-induced apoptosis in PC-3 castration resistant metastatic prostate cancer cells (mCRPC) through the hallmarks of apoptosis. The recovery of PC-3 cells from apoptosis upon removal of CBZ at different recovery periods was evaluated by Annexin V, DNA damage, oxidative damage, mitochondrial membrane depolarization, and caspase activation. Our results showed that the administration of CBZ caused apoptosis for 72 h in PC-3 cells. However, recovered cells exhibited decreased nuclear damage, plasma membrane disruption, ROS level, release cytochrome c level and caspase-3 activation with upregulation of Bcl-2 expression upon removal of especially 1 nM CBZ for 24 h recovery period in PC-3 cells. Our study indicates that CBZ treated PC-3 cells can recover after apoptotic cell death. However, advanced molecular analysis should elucidate the relationship between the molecular mechanisms of recovery and taxane response or resistance in PC-3 mCRPC cells.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] YAP is closely correlated with castration-resistant prostate cancer, and downregulation of YAP reduces proliferation and induces apoptosis of PC-3 cells
    Sheng, Xia
    Li, Wen-Bin
    Wang, De-Lin
    Chen, Ke-Hong
    Cao, Jian-Jia
    Luo, Zhao
    He, Jiang
    Li, Mei-Cai
    Liu, Wu-Jiang
    Yu, Chao
    MOLECULAR MEDICINE REPORTS, 2015, 12 (04) : 4867 - 4876
  • [2] Metastatic castration-resistant prostate cancer
    Henriques, Vanessa
    Wenzel, Mike
    Demes, Melanie-Christin
    Koellermann, Jens
    PATHOLOGE, 2021, 42 (04): : 431 - 438
  • [3] Management of Castration-Resistant, Taxane-Resistant Prostate Cancer
    Beer, Tomasz M.
    ONCOLOGY-NEW YORK, 2017, 31 (08): : 633 - 636
  • [4] Imipramine Inhibits Migration and Invasion in Metastatic Castration-Resistant Prostate Cancer PC-3 Cells via AKT-Mediated NF-κB Signaling Pathway
    Lim, Eun Yeong
    Park, Joon
    Kim, Yun Tai
    Kim, Min Jung
    MOLECULES, 2020, 25 (20):
  • [5] Addressing taxane resistance in metastatic castration-resistant prostate cancer: a focus on chaperone proteins
    Hotte, Sebastien J.
    FUTURE ONCOLOGY, 2017, 13 (04) : 369 - 379
  • [6] Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer
    Rini, Brian I.
    CURRENT ONCOLOGY REPORTS, 2009, 11 (03) : 163 - 164
  • [7] Circulating tumor cells in metastatic castration-resistant prostate cancer
    Brian I. Rini
    Current Oncology Reports, 2009, 11 : 163 - 164
  • [8] Olaparib in Metastatic Castration-Resistant Prostate Cancer
    Biswas, Bivas
    Ganguly, Sandip
    Ghosh, Joydeep
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (12): : 1174 - 1175
  • [9] Biomarkers in Metastatic Castration-resistant Prostate Cancer
    Miller, K.
    AKTUELLE UROLOGIE, 2015, 46 (01) : 66 - 70
  • [10] Olaparib in metastatic castration-resistant Prostate Cancer
    Lorenz, Judith
    AKTUELLE UROLOGIE, 2022, 53 (02)